Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-RANKL monoclonal antibody HS-20090

An immunoglobulin G2 (IgG2) monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL), with antiosteoclast activity. Upon administration, anti-RANKL monoclonal antibody HS-20090 specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces. This results in an inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation.
Code name:HS 20090
HS-20090
HS20090
Search NCI's Drug Dictionary